/ILMN
ILMN Stock - Illumina, Inc.
Healthcare|Medical - Diagnostics & ResearchNASDAQ
$146.99+0.99%
+$1.44 (+0.99%) • Jan 13
53
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).16
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.64
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-17.1%upside
Target: $121.85
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ILMN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$145.52 – $148.46
TARGET (TP)$121.89
STOP LOSS$135.23
RISK/REWARD1:-2.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.41
52W High$153.06
52W Low$68.70
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $4.37B | $4.50B | $4.58B | $4.53B | $3.24B |
| Gross Profit | $2.86B | $2.74B | $2.97B | $3.15B | $2.20B |
| Gross Margin | 65.4% | 60.9% | 64.8% | 69.7% | 68.0% |
| Operating Income | $-833,000,000 | $-1,069,000,000 | $-4,179,000,000 | $-123,000,000 | $580.00M |
| Net Income | $-1,223,000,000 | $-1,161,000,000 | $-4,404,000,000 | $762.00M | $656.00M |
| Net Margin | -28.0% | -25.8% | -96.1% | 16.8% | 20.3% |
| EPS | $-7.69 | $-7.35 | $-28.05 | $5.08 | $4.46 |
Company Overview
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
11
39%
Hold / Neutral
14
50%
Sell / Underperform
3
11%
Analyst Consensus🔴 Bearish
11 Bullish17 Neutral/Bearish
Price Targets
$159
Average Target
↑ 8.0% Upside
Now
$90
Low
$159
Average
$282
High
Based on 31 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 12th 2025 | Daiwa Securities | Downgrade | Neutral | $94 |
| July 11th 2025 | Scotiabank | Downgrade | Sector Perform | $125 |
| March 4th 2025 | Citigroup | Reiterated | Neutral | $90← $130 |
| February 28th 2025 | HSBC Securities | Downgrade | Hold | $100 |
| February 10th 2025 | Barclays | Downgrade | Underweight | $100← $130 |
| February 7th 2025 | TD Cowen | Downgrade | Hold | $140← $177 |
| December 11th 2024 | Citigroup | Downgrade | Neutral | $165← $190 |
| November 12th 2024 | Morgan Stanley | Resumed | Equal Weight | $156 |
| October 17th 2024 | HSBC Securities | Upgrade | Buy | $180 |
| August 28th 2024 | Argus | Upgrade | Buy | - |
| August 16th 2024 | Daiwa Securities | Upgrade | Buy | $154← $120 |
| August 14th 2024 | TD Cowen | Upgrade | Buy | $144← $126 |
| August 14th 2024 | Barclays | Upgrade | Equal Weight | $125 |
| July 10th 2024 | Citigroup | Upgrade | Buy | $140 |
| June 3rd 2024 | Jefferies | Resumed | Hold | $115 |
Earnings History & Surprises
ILMNBeat Rate
83%
Last 18 quarters
Avg Surprise
+177.6%
EPS vs Estimate
Beats / Misses
15/3
Last 12 quarters
Latest EPS
$1.34
Q4 2025
EPS Surprise History
Q1 24
+686.1%
$0.14vs$0.02
Q2 24
+106.4%
$0.09vs$0.04
Q3 24
+228.5%
$0.36vs$0.11
Q4 24
+29.7%
$1.14vs$0.88
Q1 25
-6.5%
$0.86vs$0.92
Q2 25
+3.2%
$0.97vs$0.94
Q3 25
+16.7%
$1.19vs$1.02
Q4 25
+14.5%
$1.34vs$1.17
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 5, 2026 | $1.22 | — | — | — |
Q4 2025 | Oct 30, 2025 | $1.17 | $1.34 | +14.5% | ✓ BEAT |
Q3 2025 | Jul 31, 2025 | $1.02 | $1.19 | +16.7% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $0.94 | $0.97 | +3.2% | ✓ BEAT |
Q1 2025 | Feb 6, 2025 | $0.92 | $0.86 | -6.5% | ✗ MISS |
Q4 2024 | Nov 4, 2024 | $0.88 | $1.14 | +29.7% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $0.11 | $0.36 | +228.5% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $0.04 | $0.09 | +106.4% | ✓ BEAT |
Q1 2024 | Feb 8, 2024 | $0.02 | $0.14 | +686.1% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $0.13 | $0.33 | +153.8% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $0.02 | $0.32 | +1636.3% | ✓ BEAT |
Q2 2023 | Apr 25, 2023 | $0.03 | $0.08 | +215.8% | ✓ BEAT |
Q1 2023 | Feb 7, 2023 | $0.19 | $0.14 | -26.3% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $0.29 | $0.34 | +17.2% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $0.63 | $0.57 | -9.5% | ✗ MISS |
Q2 2022 | May 5, 2022 | $0.87 | $1.07 | +23.0% | ✓ BEAT |
Q1 2022 | Feb 10, 2022 | $0.49 | $0.75 | +53.1% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $1.24 | $1.45 | +16.9% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $1.36 | $1.87 | +37.5% | ✓ BEAT |
Latest News
Illumina Launches Billion Cell Atlas, World's Largest Genetic Perturbation Dataset, Partnering With AstraZeneca, Merck And Eli Lilly To Accelerate AI-Driven Drug Discovery
📈 PositiveBenzinga•Jan 13, 2026, 02:17 PM•Also: , ,
Illumina Reports Q4 2025 Revenue Of $1.155B, GAAP EPS $2.14–$2.17, Non-GAAP EPS $1.27–$1.30; FY2025 Revenue $4.34B, GAAP EPS $5.42–$5.45, Non-GAAP EPS $4.76–$4.79
➖ NeutralBenzinga•Jan 13, 2026, 02:12 PM
Illumina names former NIH official as medical chief; commercial chief joins Quanterix
➖ NeutralSeeking Alpha•Jan 9, 2026, 04:51 PM•Also:
TD Cowen Maintains Hold on Illumina, Raises Price Target to $140
➖ NeutralBenzinga•Jan 7, 2026, 06:11 PM
Illumina shares are trading higher after Guggenheim maintained the stock with a Buy rating and raised its price target from $114 to $144.
📈 PositiveBenzinga•Jan 5, 2026, 08:58 PM
Guggenheim Maintains Buy on Illumina, Raises Price Target to $144
📈 PositiveBenzinga•Jan 5, 2026, 05:01 PM
Canaccord Genuity Maintains Hold on Illumina, Raises Price Target to $130
➖ NeutralBenzinga•Dec 22, 2025, 12:51 PM•Also:
Barclays Maintains Underweight on Illumina, Raises Price Target to $110
➖ NeutralBenzinga•Dec 15, 2025, 09:01 PM•Also:
JP Morgan Maintains Neutral on Illumina, Raises Price Target to $130
➖ NeutralBenzinga•Dec 15, 2025, 07:10 PM
Illumina Invests In MyOme, Announcing Collaboration To Advance Proactive Health Trial Using WGS With AI Risk Models For Chronic, Rare Diseases And Cancer
📈 PositiveBenzinga•Dec 11, 2025, 02:22 PM
Illumina Study Published In 'Nature' Shows Whole-Genome Sequencing With DRAGEN Captures Nearly 90% Of Genetic Signal In Complex Diseases, Solving "Missing Heritability"
📈 PositiveBenzinga•Nov 12, 2025, 05:02 PM
CNBC Halftime Report Final Trades: Morgan Stanley, Cisco Systems, Illumina, FTAI Aviation
➖ NeutralBenzinga•Nov 10, 2025, 06:00 PM•Also: ,
Illumina Protein Prep Expands Global Proteomics Access, Processing Samples Across 16 Sites
📈 PositiveBenzinga•Nov 10, 2025, 05:21 PM
Illumina Files For Notes Offering, Size Not Disclosed
➖ NeutralBenzinga•Nov 10, 2025, 02:27 PM
China's Ministry Of Commerce Announces It Will Lift The Export Ban On Illumina Effective November 10, 2025
📈 PositiveBenzinga•Nov 5, 2025, 10:23 PM
Barclays Maintains Underweight on Illumina, Raises Price Target to $100
➖ NeutralBenzinga•Oct 31, 2025, 08:53 PM•Also:
Canaccord Genuity Maintains Hold on Illumina, Raises Price Target to $112
➖ NeutralBenzinga•Oct 31, 2025, 08:33 PM•Also:
JP Morgan Maintains Neutral on Illumina, Raises Price Target to $105
➖ NeutralBenzinga•Oct 31, 2025, 06:38 PM
TD Cowen Maintains Hold on Illumina, Raises Price Target to $115
➖ NeutralBenzinga•Oct 31, 2025, 05:53 PM
UBS Maintains Neutral on Illumina, Raises Price Target to $120
➖ NeutralBenzinga•Oct 31, 2025, 03:48 PM
Frequently Asked Questions about ILMN
What is ILMN's current stock price?
Illumina, Inc. (ILMN) is currently trading at $146.99 per share. The stock has moved +0.99% today.
What is the analyst price target for ILMN?
The average analyst price target for ILMN is $121.89, based on 1 analyst.
What sector is Illumina, Inc. in?
Illumina, Inc. operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.
What is ILMN's market cap?
Illumina, Inc. has a market capitalization of $22.46 billion, making it a large-cap company.
Does ILMN pay dividends?
No, Illumina, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorDGX
Quest Diagnostics Incorporated
$179.96
Mkt Cap: $20.1B
GMAB
Genmab A/S
$33.87
Mkt Cap: $20.9B
HOLX
Hologic, Inc.
$74.87
Mkt Cap: $16.7B
ICLR
ICON Public Limited Company
$183.29
Mkt Cap: $14.0B
LH
Labcorp Holdings Inc.
$253.98
Mkt Cap: $21.1B
MEDP
Medpace Holdings, Inc.
$608.43
Mkt Cap: $17.1B
THC
Tenet Healthcare Corporation
$199.19
Mkt Cap: $17.5B
WAT
Waters Corporation
$394.03
Mkt Cap: $23.5B
WST
West Pharmaceutical Services, Inc.
$271.83
Mkt Cap: $19.6B
ZBH
Zimmer Biomet Holdings, Inc.
$88.34
Mkt Cap: $17.5B
Explore stocks similar to ILMN for comparison